Geoffroy Canlorbe1, Sophie Matheron2, Laurent Mandelbrot3, Barbara Oudet1, Dominique Luton1, Elie Azria4. 1. Department of Gynecology and Obstetrics, Hôpital Bichat-Claude Bernard, Université Paris Diderot, Paris, France; Hospital and University Departments of Risk in Pregnancy, Paris, France. 2. Department of Infectious and Tropical Infections, Hôpital Bichat-Claude Bernard, Université Paris Diderot, Paris, France; Infection, Antimicrobials, Modeling, and Evolution Unité Mixte de Recherche 1137, French Institute of Health and Medical Research, Paris, France. 3. Hospital and University Departments of Risk in Pregnancy, Paris, France; Department of Gynecology and Obstetrics, Assistance Publique-Hôpitaux de Paris Hôpital Louis Mourier, Colombes, France. 4. Department of Gynecology and Obstetrics, Hôpital Bichat-Claude Bernard, Université Paris Diderot, Paris, France; Hospital and University Departments of Risk in Pregnancy, Paris, France; Obstetric, Perinatal, and Pediatric Epidemiology Team, Epidemiology and Biostatistics Center, Institute of Health and Medical Research Unité 1153, Sorbonne Paris Cité Center, Paris, France. Electronic address: eazria@hpsj.fr.
Abstract
OBJECTIVE: Data from the international literature suggest that there may be an association between maternal human immunodeficiency virus (HIV) infection and vasculoplacental complications during pregnancy. Studies on this subject have reached discordant conclusions. The aim of this study was to assess the incidence of vasculoplacental complications during pregnancy in women with and without HIV infection. STUDY DESIGN: This single-center case-control study compared the incidence of pregnancy-related hypertension, preeclampsia, eclampsia, and vascular intrauterine growth restriction in 280 women with HIV and 560 women not infected with HIV, matched for age, parity, and geographic origin. RESULTS: The incidence rates of pregnancy-related hypertension, preeclampsia, eclampsia, and vascular growth restriction did not differ between the women with and without HIV infection. The overall incidence of vasculoplacental complications did not differ between the 2 groups (7.5% vs 9.8%, respectively; P = .27). The risk of these was not associated with exposure to antiretroviral treatments, viral load, or CD4 T-cell counts at the beginning of pregnancy. CONCLUSION: This study shows no difference in the incidence of vasculoplacental complications between women with and without HIV infection.
OBJECTIVE: Data from the international literature suggest that there may be an association between maternal human immunodeficiency virus (HIV) infection and vasculoplacental complications during pregnancy. Studies on this subject have reached discordant conclusions. The aim of this study was to assess the incidence of vasculoplacental complications during pregnancy in women with and without HIV infection. STUDY DESIGN: This single-center case-control study compared the incidence of pregnancy-related hypertension, preeclampsia, eclampsia, and vascular intrauterine growth restriction in 280 women with HIV and 560 women not infected with HIV, matched for age, parity, and geographic origin. RESULTS: The incidence rates of pregnancy-related hypertension, preeclampsia, eclampsia, and vascular growth restriction did not differ between the women with and without HIV infection. The overall incidence of vasculoplacental complications did not differ between the 2 groups (7.5% vs 9.8%, respectively; P = .27). The risk of these was not associated with exposure to antiretroviral treatments, viral load, or CD4 T-cell counts at the beginning of pregnancy. CONCLUSION: This study shows no difference in the incidence of vasculoplacental complications between women with and without HIV infection.
Authors: Risa M Hoffman; Caitlin Newhouse; Brian Chu; Jeffrey S A Stringer; Judith S Currier Journal: Curr HIV/AIDS Rep Date: 2021-01-05 Impact factor: 5.071
Authors: Kristi R Van Winden; Allison Bearden; Naoko Kono; Toni Frederick; Eva Operskalski; Alice Stek; Raj Pandian; Lorayne Barton; Andrea Kovacs Journal: Am J Perinatol Date: 2019-07-31 Impact factor: 3.079